The urokinase plasminogen activator system in cancer: a putative therapeutic target?
S Killeen1, A Hennessey, Y El Hassan
1Department of Surgery, Kerry General Hospital, Tralee, Co. Kerry, Ireland. sdfkilleen@eircom.net
Abstract:
The urokinase plasminogen activator (uPA) system is an endogenous proteolytic cascade which can be actively subverted by the neoplastic process to facilitate progression and metastasis. Abundant experimental and clinical evidence supports such a role and elevated levels of components of the uPA system are strong negative prognosis indicators in a wide variety of tumor types. Collectively this data makes the uPA system an attractive option for targeted intervention. This review examines the role of the uPA system in tumor invasion and metastasis and assess the various therapeutic modalities developed to selectively exploit this system.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Clot Retraction and Fibrinolysis

